**Core Concept**
Hybridoma technology is a method used to produce large quantities of monoclonal antibodies (mAbs) in vitro. It involves the fusion of antibody-producing B cells (B lymphocytes) with myeloma cells (cancerous plasma cells) to create a hybrid cell line that can continuously produce specific antibodies.

**Why the Correct Answer is Right**
The hybridoma technology was first developed by Georges Köhler and César Milstein in 1975. This technique allows for the production of large quantities of homogeneous antibodies with specific antigen-binding properties. The resulting hybridoma cells are immortal, meaning they can grow indefinitely in culture, and can be screened for antibody production. The antibodies produced by these cells are called monoclonal antibodies (mAbs), which are characterized by their uniform structure and specificity for a particular antigen.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately describe the hybridoma technology.
**Option B:** This option is incorrect because it does not correctly explain the purpose of hybridoma cells.
**Option C:** This option is incorrect because it does not accurately describe the application of hybridoma technology.

**Clinical Pearl / High-Yield Fact**
Hybridoma technology has revolutionized the field of immunology and has led to the development of numerous life-saving therapeutic antibodies, including those used in the treatment of cancer, autoimmune diseases, and infectious diseases.

**Correct Answer:** A. Hybridoma technology involves the fusion of antibody-producing B cells with myeloma cells to create a hybrid cell line that can continuously produce specific antibodies.